STUDY OF ORAL VERSUS INTRAVENOUS IRON THERAPY IN POSTPARTUM ANAEMIC WOMEN

Sharmila Pradhan¹, Ojaswini Patel², Malayiltharayil Deepti Raju³, Pragyan Dash⁴

¹Assistant Professor, Department of Obstetrics and Gynaecology, VIMSAR, Burla.

²Associate Professor, Department of Obstetrics and Gynaecology, VIMSAR, Burla.

³Junior Resident, Department of Obstetrics and Gynaecology, VIMSAR, Burla.

⁴Junior Resident, Department of Obstetrics and Gynaecology, VIMSAR, Burla.

ABSTRACT**BACKGROUND**

Anaemia is a serious nutrition problem affecting millions in developing countries and remains a major challenge for human health and social and economic development. Iron deficiency is thought to be the most common cause of anaemia globally.

MATERIALS AND METHODS

It was a prospective randomised controlled trial, single centric study involving women with postpartum IDA. Improvements of those who were treated with injectable iron were compared with those who were treated with oral iron.

RESULTS

The demographic variables like age, BMI, habitat, dietary habits, parity, antenatal presence of anaemia, modes of delivery and type of risk factors were comparable. In oral iron therapy group, mean Hb on Day 0 was 8.008 ± 0.5435 gm/dL. On 2nd week mean Hb rises to 8.924 ± 0.7660 gm/dL and on 6th week mean Hb rises to 9.889 ± 0.9467 gm/dL. In injectable iron therapy group mean Hb on Day 0 was 7.822 ± 0.5422 gm/dL, in the 2nd week mean rise in Hb was 10.362 ± 0.9354 gm/dL and in 6th week Hb rise was 12.858 ± 0.6616 gm/dL.

CONCLUSION

Intravenous iron therapy administration increases the haemoglobin level and iron store more rapidly than oral iron intake in women with iron deficiency anaemia in the postnatal period. It can be used as safe and effective alternative to blood transfusion and oral iron therapy in the treatment of iron deficiency anaemia in the postpartum period. If cost is not a limiting factor, limited dosage schedule of iron sucrose as prescribed in the study is a safe and effective alternative to daily oral iron taken in treatment of postpartum anaemia. Multiple child birth, poor socioeconomic status, dietary habits, type of habitat and education status of mother also contributed to the incidence of postpartum anaemia.

KEYWORDS

Iron Deficiency Anaemia, Serum Iron, Serum Ferritin, Postpartum.

HOW TO CITE THIS ARTICLE: Pradhan S, Patel O, Raju MD, et al. A study of oral versus intravenous iron therapy in postpartum anaemic women. J. Evolution Med. Dent. Sci. 2017;6(54):4101-4106, DOI: 10.14260/Jemds/2017/886

BACKGROUND

Anaemia is a serious nutrition problem affecting millions in developing countries and remains a major challenge for human health and social and economic development. Anaemia is a condition in which the number of red blood cells or their oxygen-carrying capacity is insufficient to meet physiologic needs which vary by age, sex, altitude, smoking and pregnancy status. Anaemia in pregnancy is defined by WHO as Haemoglobin below 11 gm/dL.^[1] It is recommended that postpartum anaemia should be defined by haemoglobin < 11 g/dL at 1 week postpartum and < 12 g/dL at 8 weeks postpartum. The major causes of postpartum anaemia are prepartum anaemia combined with acute bleeding anaemia due to blood losses at delivery.^[2] In consecutive European women, the prevalence of anaemia 48 hrs. after delivery is

approximately 50%. In developing countries, the prevalence of postpartum anaemia is in the range of 50 - 80%.^[3] There are various possible forms of treatment for post-partum iron deficiency anaemia.

Iron can be given orally by intramuscular route or intravenous method. Oral iron therapy can be used for mild anaemia, while intravenous and intramuscular iron therapy can be given in patients with severe anaemia.^[1] There are cases where parenteral iron is preferable over oral iron. These are cases where oral iron is not tolerated, where the haemoglobin needs to be increased quickly, where there is an underlying inflammatory condition or renal patients, the benefits of parenteral iron far outweigh the risks.^[4]

We are in search of an iron preparation, which can increase the haemoglobin in shorter interval with fewer side effects. Here, we have chosen iron sucrose to see the results mainly in respect of time taken for the increase in haemoglobin and serum ferritin.

Aims and Objectives

The Primary aim is to evaluate the efficacy of intravenous (newer molecule-iron sucrose) iron compared to oral iron therapy in the management of Iron Deficiency Anaemia (IDA) in postpartum anaemia. The Secondary aim is to analyse the prevalence of postpartum anaemia in rural setup, the effect of

Financial or Other, Competing Interest: None.

Submission 30-05-2017, Peer Review 23-06-2017,

Acceptance 29-06-2017, Published 06-07-2017.

Corresponding Author:

Dr. Ojaswini Patel,

Behind Patel Nursing Home,

Kirba, Burla,

Sambalpur-768018, Odisha.

E-mail: drojaswinipatel@yahoo.co.in

DOI: 10.14260/Jemds/2017/886

use of intravenous iron sucrose complex in improvement of haemoglobin levels and serum ferritin and to study the adverse effect of these therapies in both groups.

MATERIALS AND METHODS

It was a prospective randomised controlled trial; single centric study was conducted in the Dept. of Obstetrics and Gynaecology, VSSIMSAR, Burla for the duration of 2 years, November 2014 to November 2016. Ethical Committee Clearance was obtained before commencing the study. All patients were enrolled after duly signed informed consent. After careful history taking, clinical examination and minimal investigations, other causes of anaemia were ruled out. The initial iron status of the woman was assessed by the clinical and laboratory examinations (complete blood picture and serum ferritin levels). A total of 100 postpartum women who had developed postpartum IDA (having Hb levels between 7 - 9 gm/dL and serum ferritin level less than 15 µg/mL at 24 - 48 hours post-delivery) were included in the study based on inclusion and exclusion criteria. All 100 women were allotted serial number of 1 - 100, those having odd numbers were recruited in Group A and those having even numbers were recruited in Group B, each group having 50 members.

Group A (Injectable Iron Therapy Group)

50 patients included in this group received divided dose of intravenous ferrous sucrose calculated according to body weight and Hb deficit.

Dose Calculated

In postpartum anaemia = $2.4 \times W \times D + 500$

W= Weight of patient in kg

D= Target Hb- Actual Hb

Target haemoglobin in postpartum anaemia= 12 gm/dL.

500 mg for body iron stores in lactation.

2.4 - from blood volume which is 7% of body weight and iron content of Hb, which is $0.34\% \times 0.07 \times 0.0034 \times 100 = 2.4$ (Conversion from g/dL to mg).

Iron sucrose is given by IV injection according to iron deficit calculated and rounded up to nearest multiple of 100

for each individual; 200 mg of elemental iron diluted in 200 mL normal 0.9% saline was maximum dose given as slow IV over 30 mts in the study and was repeated on alternate days when necessary. Treatment was stopped after administration of the calculated dose. Patients during the treatment were monitored for any signs and symptoms of reactions.

Group B (Oral Ferrous Sulphate Group)

50 patients included in this group were advised to take 200 mg of ferrous sulphate twice daily for 6 weeks. Women were advised to document treatment compliance and symptoms.

Blood samples of patients were taken at the day of recruitment into the study (Day 0) and the rest of the samples were taken in 2 weeks and 6 weeks after the start of the treatment to detect any difference in the speed of restoration of Haemoglobin and serum ferritin. Improvement of mean haemoglobin, mean serum ferritin level, adverse reactions tolerability of Group A (injectable iron) compared with Group B (oral ferrous sulphate iron).

Statistical analysis (mean, standard deviation, unpaired t-test) was done by SPSS Inc. USA. Confidence interval (95%) of various proportions was calculated. $P < 0.05$ was taken as significant.

Inclusion Criteria

The study population consisted of women with postpartum IDA (defined as Hb of between 7 to 9 gm/dL and serum ferritin of < 15 micrograms/L at 24 - 48 hours post-delivery).

Exclusion Criteria

The women with previous iron therapy during pregnancy, intolerance to iron derivatives, peripartum blood transfusion or a history of asthma, thromboembolism, seizures, alcohol or drug abuse. Women with signs of infection or evidence of renal or hepatic dysfunction patients with sickle cell anaemia, thalassemia, megaloblastic anaemia and other types of anaemia except iron deficiency anaemia.

RESULTS

Parameters	Oral Iron	Iron Sucrose	P
Mean age (in years)	25.34 ±3.836	23.7 ± 3.775	0.832
BMI	21.2774± 2.328	21.1632±1.471	0.640
Habitat (rural/urban)	31/19(62%/39%)	32/18(64%/36%)	0.063
Dietary habits (non-veg/veg)	37/13(74%/26%)	38/12(76%/24%)	0.879
Parity (primi/multi)	23/27(46%/54%)	18/32(36%/64%)	1.033
Antenatal anaemia	31(62%)	34(68%)	0.523
Delivery (LSCS/VD)	28/22(56%/44%)	38/12(76%/24%)	0.03
Type of risk factor			
PPH	16(32%)	13(26%)	0.5777
Hypertensive disorder	19(38%)	17(34%)	0.7388
Placenta previa	4(8%)	7(14%)	0.365
Multiple pregnancy	4(8%)	5(10%)	0.738
Exclusive breast feeding/non-exclusive	17/33(34%/66%)	16/34(32%/68%)	0.831
Baseline Hb (gm/dL)	8.008±0.543	7.822±0.542	0.7
Baseline ferritin (µg/dL)	11.5796±0.680	11.9206±0.936	0.05

Table 1. Demographic Variables and Baseline Clinical Data

The demographic variables like age, BMI, habitat, dietary habits, parity, antenatal presence of anaemia, modes of delivery and type of risk factors were comparable ($p > 0.05$).

Delivery by caesarean section, postpartum haemorrhage, hypertensive disorders of pregnancy, placenta previa and multiple gestations were among the leading risk factors.

Baseline Hb in oral iron therapy group was 8.008 ± 0.543 gm/dL and serum ferritin was 11.5796 ± 0.680 μ g/L.

Baseline Hb in injectable iron therapy group was 7.822 ± 0.542 gm/dL and serum ferritin was 11.9206 ± 0.936 μ g/L.

Distribution of Patients according to Habitat

Among the patients with postpartum anaemia in my study group, 63% belonged to rural area and rest 37% belonged to urban area.^[5]

Parity	Oral iron Therapy Group	Injectable Iron Therapy Group	Total
Primiparous	23(46%)	18(36%)	41
Multiparous	27(54%)	32(64%)	59

Table 2. Distribution of Patients according to Parity

Above table shows most of the patients were multigravida 59% and rest 41% were primigravida. In oral group, 46% were primiparous and 54% were multiparous. In injectable group, 36% were primiparous and 64% were multiparous.^[6]

Graph 1. Distribution of Patients according to Parity

Age Wise Distribution of Postpartum Anaemic Patients based on Oral and Intravenous Iron Therapy Group

In Oral Iron Therapy group 8% patients were under 20 years of age, 38% were between 20 - 24 years, 40% patients were between 25 - 29 years of age and 7 were above 30.

In Injectable group of iron therapy 18% were below 20 years of age, 44% were between 20 - 24, 30% were between 25 - 29 and 8% were above 30 years of age.^[7]

Hb gm%	Oral Iron			Injectable Iron		
	Day 0	2 Weeks	6 Weeks	Day 0	2 Weeks	6 Weeks
7-8	20(40%)	4(8%)	0	28(56%)	00	00
8-9	30(60%)	18(36%)	8(16%)	22(44%)	2(4%)	00
9-10	00	22(44%)	17(34%)	00	16(32%)	00
10-11	00	6(12%)	11(22%)	00	14(28%)	00
11-12	00	00	13(26%)	00	16(32%)	5(10%)
≥ 12	00	00	1(2%)	00	2(4%)	45(90%)
Total	50	50	50	50	50	50

Table 5. Comparison between the Two Modalities of Iron Therapy in Relation to Improvement in Haemoglobin Levels

Education Status Distribution of Post-Partum Anaemic Patients based on Oral and Intravenous Iron Therapy Group

In Oral Iron Therapy group 34% were illiterate, 22% had primary education, 28% had secondary education and 16% were graduated. In Intravenous Iron Therapy group 22% were illiterate, 38% had primary education, 30% had secondary education and 10% were graduates.^[8]

Socioeconomic Status	No. of Patients	Percentage
1	39	39
2	37	37
3	24	24

Table 3. Distribution of Patients according to Socio-Economic Status

Graph 2: Distribution of Patients according to Socio-Economic Status

1- < Rs. 10000/month, 2- Rs. 10000 - 20000/month, 3- > Rs. 20000/month.

Most of the patients belonged to group 1 (39%), group 2 (37%) and 24% patients belonged to group 3.

Socioeconomic Status (Group)	Oral Iron Therapy Group	Intravenous Iron Therapy Group	Total
1	19(38%)	20(40%)	39
2	18(36%)	19(38%)	37
3	13((26%)	11(22%)	24
	50	50	100

Table 4. Socioeconomic Distribution of Postpartum Anaemic Patients based on Oral and Intravenous Iron Therapy Group

In the oral group 38% were in group 1, 36% in group 2 and 26% in group 3. In the intravenous iron therapy group 40% were in group 1, 38% in group 2 and 22% in group 3.^[9]

In the Oral Iron Therapy group, 40% patients were having Hb between 7 - 8 gm/dL and 60% patients were having between 8 - 9 gm/dL.

After treatment on oral iron therapy in 2 weeks nearly 44% patients showed increase in Hb to 9 - 10 gm/dL, 12% patients between 10 - 11 gm/dL, 36% patients between 8 - 9 gm/dL, while 4% patients still had Hb between 7 - 8 gm/dL.

In the 6th week, only 2% patients showed rise in Hb to ≥ 12 gm/dL; 26% patients had Hb between 11 - 12 gm/dL, 22% had risen in Hb between 10 - 11 gm/dL and 34% patients had Hb between 9 - 10 gm/dL, but 16% patients were still having Hb between 8 - 9 gm/dL.

In Injectable Iron Therapy Group

On Day 0, 44% patients had Hb between 8 - 9 gm/dL and 56% patients had Hb between 7 - 8 gm/dL.

In the 2nd week 4% patients showed rise in Hb to ≥ 12 gm/dL, 32% patients had rise in Hb to 11 - 12 gm/dL, 28% patients had risen between 10 - 11 gm/dL, 32% patients had rise in Hb between 9 - 10 gm/dL and 4% patients remained between 8 - 9 gm/dL.

In the 6th week, 90% patients showed rise in Hb ≥ 12 gm/dL and 10% patients had Hb between 11 - 12 gm/dL.

Serum Ferritin (μ G/L)	Oral Iron			Injectable Iron		
	Day 0	2 Weeks	6 Weeks	Day 0	2 Weeks	6 Weeks
<15	50	46(92%)	28(56%)	50	00	00
15-50	00	4(8%)	22(44%)	00	42(84%)	11(22%)
>50	00	00	00	00	8(16%)	39(78%)
	50	50	50	50	50	50

Table 6. Comparison between Two Modalities of Iron Therapy in relation to Improvement in Serum Ferritin Level

Oral Iron Therapy Group

After treatment in 2nd week, 46 (92%) patients had serum ferritin below 15 μ G/L and 4 (8%) patients had serum ferritin between 15 - 50 μ G/L. In the 6th week, 22 (44%) patients had serum ferritin between 15 - 50 μ G/L and 28 (56%) still had serum ferritin below 15 μ G/L.

Injectable Iron Therapy Group

In the 2nd week nearly 16% patients showed rise in serum ferritin > 50 μ G/L and 84% patients had serum ferritin between 15 - 50 μ G/L. In the 6th week, 78% patients had rise in serum ferritin > 50 μ G/L and 22% patients had serum ferritin between 15 - 50 μ G/L.

Graph 3. Comparison between Two Modalities of Iron Therapy in relation to Improvement in Serum Ferritin Level

Haemoglobin	Mean Hb in Oral Iron Group	Standard Deviation	Mean Hb in Injectable Group	Standard Deviation	P value
Day 0	8.008	0.5435	7.822	0.5422	0.7
2 weeks	8.924	0.7660	10.362	0.9354	0.001
6 weeks	9.889	0.9467	12.858	0.6616	0.0001*

Table 7. Comparison of Mean and Standard Deviation in Haemoglobin Level in both Treatment Modalities

In oral iron therapy group, mean Hb on Day 0 was 8.008 ± 0.5435 gm/dL. On 2nd week, rise in mean Hb was 8.924 ± 0.7660 gm/dL and on 6th week mean rise in Hb was 9.889 ± 0.9467 gm/dL.

In injectable iron therapy group mean Hb on Day 0 was 7.822 ± 0.5422 gm/dL, in the 2nd week mean rise in Hb was 10.362 ± 0.9354 gm/dL and in 6th week Hb rise was 12.858 ± 0.6616 gm/dL. These values were found to be statistically significant with p value of < 0.05 and < 0.0001 for 2nd and 6th week respectively.

Graph 4. Comparison of Mean and Standard Deviation in Haemoglobin Level in both Treatment Modalities

Serum Ferritin	Mean Serum Ferritin in Oral Iron Group	Standard Deviation	Mean Serum Ferritin in Injectable Group	Standard Deviation	P value
Day 0	11.579	0.6809	11.920	0.9369	0.05
2 weeks	13.057	1.033	48.907	1.542	0.001
6 weeks	15.063	1.089	53.885	5.111	0.00001*

Table 8. Mean and Standard Deviation of Serum Ferritin in both Treatment Modalities

In oral group of iron therapy, mean serum ferritin was 11.579 ± 0.6809 μ G/L on Day 0, which showed rise in mean serum ferritin to 13.057 ± 1.033 μ G/L in 2nd week and in 6th week it had increased to 15.063 ± 1.089 μ G/L.

In the injectable iron group on Day 0 mean serum ferritin was 11.920 ± 0.9369 μ G/L, in 2nd week mean serum ferritin was 48.907 ± 1.542 μ G/L and mean serum ferritin was 53.885 ± 5.111 μ G/L in 6th week.^[10]

Above values were found to be statistically significant with p value < 0.05 and < 0.00001 in 2nd and 6th week respectively.^[11]

Graph 5. Mean and Standard Deviation of Serum Ferritin in both Treatment Modalities

Adverse Effects of Oral Iron	No. of Patients	%	Adverse Effects of Injectable Iron	No. of Patients	%
Heartburn	02	4%	Anaphylaxis	00	
Constipation	04	8%	Hypotension	00	
Vomiting	00		Headache	00	
Nausea	03	6%	Nausea	00	
Metallic taste	03	6%	Urticaria	00	
Epigastric pain	00		Flushing	03	6%
Diarrhoea	01	2%	Metallic taste	01	2%
Total	13	26%	Total	04	8%

Table 9. Adverse Reactions to Intravenous Iron Sucrose and Oral Iron Therapy

In oral iron therapy group out of total 50 patients, 13 (26%) patients had adverse reaction while taking oral iron; 2 (4%) patients had heart burn, 4 (8%) of them had constipation, 3 (6%) had nausea, 3 (6%) had metallic taste and 1 had diarrhoea.^[12]

In intravenous iron therapy group, out of 50 patients only 4 (8%) patients reported to have adverse reactions. 3 (6%) reported to have flushing and 1 (2%) had metallic taste.^[13]

DISCUSSION

Treatment of postpartum anaemia is very important to build up iron reserves in the puerperal, to have a better quality of life and to minimise incidence of anaemia in next pregnancy. So the following study was done to see whether giving iron by intravenous route in the form of iron sucrose to women with postpartum anaemia results in higher haemoglobin concentrations and improved iron stores than using standard treatment with oral iron.^{[13][14]}

In this study [Table No. 1] during the initially screening and recruitment of postpartum patients in the labour room and ward based on inclusion and exclusion criteria, 310 out of 440 mothers were found to be anaemic (70.45%). Among the anaemic cases 153 (34.7%) were having mild anaemia, 110 (25%) were having moderate anaemia and 47 (10.68%) were having severe anaemia. Three of the patients did not give consent for participating in the study and other 6

patients refused for followup. Thus, 100 patients were selected randomly based on Haemoglobin 7 - 9 gm/dL and serum ferritin < 15 µg/L.^{[15][16]}

In this study, demographic variables were compared in the two groups of oral and intravenous iron therapy in terms of age, body mass index, habitat, parity, dietary habits, presence of antenatal anaemia, modes of delivery and type of risk factors (p > 0.05). Delivery by caesarean, presence of antenatal anaemia and hypertensive disorders of pregnancy were the most common leading risk factors. Baseline haemoglobin and serum ferritin in both groups were clinically insignificant.^{[17][18]}

CONCLUSION

The present study focused on prevalence of anaemia in postpartum women and its effective management with rapid and safe modes of treatment. The present study shows that supplementing with intravenous iron sucrose have a positive response on postpartum haemoglobin level. In the iron supplemented group, the haemoglobin level tends to increase from the baseline levels. Intravenous iron therapy administration increases the haemoglobin level more rapidly than oral iron intake of in women with iron deficiency anaemia in the postnatal period. Intravenous iron therapy also replenishes iron stores more rapidly than oral iron. It can be used as safe and effective alternative to blood transfusion and oral iron therapy in the treatment of iron deficiency anaemia in the postpartum period. Compliance can be ensured with the injectable iron group; however, the cost of injectable iron is more compared to iron tablets. If cost is not a limiting factor, limited dosage schedule of iron sucrose as prescribed in the study is a safe and effective alternative to daily oral iron taken in treatment of postpartum anaemia. Multiple child birth, poor socioeconomic status, dietary habits, type of habitat and education status of mother also contributed to the incidence of postpartum anaemia. Peripartum anaemia and complications during child birth also played an important role in the occurrence of postpartum anaemia. Present study found that postpartum anaemia had affected the practice of breastfeeding. This also affects the mother and child bonding. Future perspectives should include increased awareness to prevent and diagnose postpartum anaemia including screening of women at risk. Assessment of iron status (haemoglobin, ferritin) prior to delivery will help to define women at risk for postpartum iron deficiency and anaemia. Measurement of haemoglobin 24 - 48 hours after delivery will delineate women with anaemia who are in need of treatment with iron.

It may not be possible to set up the blood bank in every remote corner of the country, but it is certainly possible to make a blood bank in the woman's body by building up her haemoglobin.

REFERENCES

- [1] <http://www.interscience.wiley.com/Cochrane>.
- [2] Milman N. Postpartum anemia I: definition, prevalence, causes, and consequences. Ann Hematol 2011;90(11):1247-53.
- [3] Breymann C, Honegger C, Holzgreve W, et al. Diagnosis and treatment of iron-deficiency anaemia during

- pregnancy and postpartum. *Arch Gynecol Obstet* 2010;282(5):577-80.
- [4] Danielson BG. Structure, chemistry and pharmacokinetics of intravenous iron agents. *J Am Soc Nephrol* 2004;15(Suppl 2):S93-8.
- [5] Zhao A, Zhang Y, Li B, et al. Prevalence of anemia and its risk factors among lactating mothers in Myanmar. *Am J Trop Med Hyg* 2014;90(5):963-7.
- [6] Bodnar LM, Scanlon KS, Freedman DS, et al. High prevalence of postpartum anemia among low-income women in the United States. *Am J Obstet Gynecol* 2001;185(2):438-43.
- [7] Ali J, Das BP, Terangpi R. Effectiveness and safety of intravenous iron sucrose therapy in moderately anaemic pregnant women in third trimester. *International Journal of Science and Research (IJSR)* 2016;5(11):38-40.
- [8] Somdatta P, Reddaiah VP, Singh B. Prevalence of anaemia in the postpartum period: a study of a North Indian village. *Trop Doct* 2009;39(4):211-5.
- [9] Goodburn EA, Gazi R, Chowdhury M. Beliefs and practices regarding delivery and postpartum maternal morbidity in rural Bangladesh. *Stud Fam Plann* 1995;26(1):22-32.
- [10] Kharde PS, Bangal VB, Panicker KK. Comparative study on intravenous iron sucrose and oral iron therapy in iron deficiency anaemia during postpartum period. *International journal of biomedical and advance reaseac (IJBAR)* 2012;3(4):238-24.
- [11] Giannoulis C, Daniilidis A, Tantanasis T, et al. Intravenous administration of iron sucrose for treating anemia in postpartum women. *Hippokratia* 2009;13(1):38-40.
- [12] Momen AK, al-Meshari A, al-Nuaim L, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. *Eur J Obstet Gynecol Reprod Biol* 1996;69(2):121-4.
- [13] Hallak M, Sharon AS, Diukman R, et al. Supplementing iron intravenously in pregnancy. A way to avoid blood transfusions. *J Reprod Med* 1997;42(2):99-103.
- [14] Bayoumeu F, Subiran-Buisset C, Baka NE, et al. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. *Am J Obstet Gynecol* 2002;186(3):518-22.
- [15] Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. *Nephron Clin Pract* 2005;100:c55-c62.
- [16] Kiran KV, Guru PB, Srinivasa RK, et al. Study of effect of intravenous iron sucrose in the treatment of puerperal anemia. *Indian Journal of Pharmacy Practice* 2010;3(4):14-7.
- [17] Verma S, Inamdar SA, Malhotra N. Intravenous iron therapy versus oral iron in postpartum patients in rural area. *Journal of SAFOG* 2011;3(2):67-70.
- [18] Rohina AS, Vineet MV, Navin PA, et al. Comparison of oral iron and IV iron sucrose for treatment of anemia in postpartum Indian women. *National Journal of Community Medicine* 2012;3(1):48-53.